A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.
Stay up to date on recent advances in oncology nursing and patient care.
Q&A: Transitioning Myeloma Care to the Community Level
Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according to Diane Moran, RN, MA, EdM.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment
Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma
A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer